These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 11387054)
21. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177 [TBL] [Abstract][Full Text] [Related]
22. Outcomes of transrectal ultrasound scan of the prostate with sector biopsies for 323 New Zealand men with suspicion of prostate cancer. Smart R N Z Med J; 1999 Dec; 112(1101):465-9. PubMed ID: 10678211 [TBL] [Abstract][Full Text] [Related]
23. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Kim JJ; Yang JS; Dang K; Manson KH; Weiner DB Clin Cancer Res; 2001 Mar; 7(3 Suppl):882s-889s. PubMed ID: 11300487 [TBL] [Abstract][Full Text] [Related]
24. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085 [TBL] [Abstract][Full Text] [Related]
25. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
26. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. DeWeese TL; van der Poel H; Li S; Mikhak B; Drew R; Goemann M; Hamper U; DeJong R; Detorie N; Rodriguez R; Haulk T; DeMarzo AM; Piantadosi S; Yu DC; Chen Y; Henderson DR; Carducci MA; Nelson WG; Simons JW Cancer Res; 2001 Oct; 61(20):7464-72. PubMed ID: 11606381 [TBL] [Abstract][Full Text] [Related]
27. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874 [TBL] [Abstract][Full Text] [Related]
28. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG; Raj GV; Moreno JG J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297 [TBL] [Abstract][Full Text] [Related]
29. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404 [TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Rochlitz C; Dreno B; Jantscheff P; Cavalli F; Squiban P; Acres B; Baudin M; Escudier B; Heinzerling L; Morant R; Herrmann R; Dietrich PY; Dummer R Cancer Gene Ther; 2002 Mar; 9(3):289-95. PubMed ID: 11896446 [TBL] [Abstract][Full Text] [Related]
31. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713 [TBL] [Abstract][Full Text] [Related]
32. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371 [TBL] [Abstract][Full Text] [Related]
33. [Questionnaire based evaluation of prostate biopsy complication comparing different bioptic schemes]. Damiano R; Oliva A; Cantiello F; Esposito C; Perdonà S; De Sio M; Bitonti M; Sacco R; D'Armiento M Arch Ital Urol Androl; 2003 Mar; 75(1):40-5. PubMed ID: 12741345 [TBL] [Abstract][Full Text] [Related]
34. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840 [TBL] [Abstract][Full Text] [Related]
35. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial. Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769 [TBL] [Abstract][Full Text] [Related]
36. Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Ferrand C; Robinet E; Contassot E; Certoux JM; Lim A; Hervé P; Tiberghien P Hum Gene Ther; 2000 May; 11(8):1151-64. PubMed ID: 10834617 [TBL] [Abstract][Full Text] [Related]
37. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512 [TBL] [Abstract][Full Text] [Related]
38. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748 [TBL] [Abstract][Full Text] [Related]
39. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Rojas-Martínez A; Manzanera AG; Sukin SW; Esteban-María J; González-Guerrero JF; Gomez-Guerra L; Garza-Guajardo R; Flores-Gutiérrez JP; Elizondo Riojas G; Delgado-Enciso I; Ortiz-López R; Aguilar LK; Butler EB; Barrera-Saldaña HA; Aguilar-Cordova E Cancer Gene Ther; 2013 Nov; 20(11):642-9. PubMed ID: 24052127 [TBL] [Abstract][Full Text] [Related]
40. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Murphy G; Tjoa B; Ragde H; Kenny G; Boynton A Prostate; 1996 Dec; 29(6):371-80. PubMed ID: 8977634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]